CytoAgents
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 S Commons Ste 102, Pittsburgh, Penns...Phone Number
(412) 303-1200Website
www.cytoagents.comRevenue
$5.4 MillionIndustry
About CytoAgents
CytoAgents is focused on developing innovative pharmaceutical products aimed at treating symptoms associated with Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Their lead product, CTO1681, is an orally bioavailable, steroid-sparing immunomodulator designed to address inflammation driven by cytokine activity in various diseases, including oncology and inflammatory conditions. The company is currently conducting clinical trials to evaluate the efficacy of CTO1681 in patients undergoing CAR T-Cell therapy, where inflammation poses significant treatment challenges. CytoAgents aims to enhance patient outcomes by providing safer and more effective treatment options for those affected by inflammatory diseases.Explore more
CytoAgents Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to CytoAgents
Compare insights from companies similar to CytoAgents, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
CytoAgents Tech Stack
A closer look at the technologies used by CytoAgents
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CytoAgents
Sign Up For FreeTo access detailed company insights
CytoAgents is focused on developing innovative pharmaceutical products aimed at treating symptoms associated with Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Their lead product, CTO1681, is an orally bioavailable, steroid-sparing immunomodulator designed to address inflammation driven by cytok... Read More
